Rubius Therapeutics, Inc. (RUBY): Price and Financial Metrics

Rubius Therapeutics, Inc. (RUBY)

Today's Latest Price: $8.92 USD

0.92 (-9.35%)

Updated Jan 17 12:00am

Add RUBY to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 322 in Biotech

See all "A" rated Strong Buy stocks

RUBY Daily Price Range
RUBY 52-Week Price Range

RUBY Stock Price Chart More Charts

RUBY Price/Volume Stats

Current price $8.92 52-week high $20.04
Prev. close $9.84 52-week low $6.96
Day low $8.81 Volume 544,600
Day high $10.05 Avg. volume 534,058
50-day MA $9.96 Dividend yield N/A
200-day MA $12.17 Market Cap 711.82M

Rubius Therapeutics, Inc. (RUBY) Company Bio

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.

RUBY Latest News Stream

Event/Time News Detail
Loading, please wait...

RUBY Latest Social Stream

Loading social stream, please wait...

View Full RUBY Social Stream

RUBY Price Returns

1-mo -21.20%
3-mo -3.46%
6-mo -34.75%
1-year -36.15%
3-year N/A
5-year N/A
YTD -6.11%
2019 -40.92%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4385 seconds.